Alex Gibson is Promoted to CEO for Edinburgh Molecular Imaging

Dr Alex Gibson has been appointed as Chief Executive Officer. Alex has over 25 years of experience in the radiopharmaceutical industry starting as a radiochemist with Amersham  (now part of GE Healthcare). Following several roles within imaging pharmaceutical R&D,...

Edinburgh Molecular Imaging Appoints New Chairman

Edinburgh Molecular Imaging appoints Dr Rob James as Non-Executive Chairman Rob is currently the Managing Partner of Sixth Element Capital and has over 20 years of experience of working in early-stage companies developing oncology drugs. He first worked at Cancer...

Results from Phase II clinical development of EMI-137 published

The work carried ou as part of Phase IIb stage of development of EMI-137 has showed FME using EMI-137 appeared to be safe andfeasible within a 1- to 3-h dose-to-imaging interval. No clinicallysignificant differences were observed among the cohorts, althougha 1-h...